Compare HLI & CRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HLI | CRL |
|---|---|---|
| Founded | 1972 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 8.6B |
| IPO Year | 2015 | 1999 |
| Metric | HLI | CRL |
|---|---|---|
| Price | $151.68 | $160.58 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 12 |
| Target Price | $194.29 | ★ $198.27 |
| AVG Volume (30 Days) | 671.6K | ★ 790.6K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.54% | N/A |
| EPS Growth | ★ 41.61 | N/A |
| EPS | ★ 4.74 | N/A |
| Revenue | ★ $2,389,416,000.00 | $1,857,601,000.00 |
| Revenue This Year | $13.77 | N/A |
| Revenue Next Year | $12.10 | $3.04 |
| P/E Ratio | $31.73 | ★ N/A |
| Revenue Growth | ★ 24.81 | 10.48 |
| 52 Week Low | $134.41 | $132.58 |
| 52 Week High | $211.78 | $228.88 |
| Indicator | HLI | CRL |
|---|---|---|
| Relative Strength Index (RSI) | 49.66 | 45.38 |
| Support Level | $146.58 | $147.22 |
| Resistance Level | $184.59 | $166.62 |
| Average True Range (ATR) | 4.68 | 8.97 |
| MACD | -0.13 | -1.18 |
| Stochastic Oscillator | 56.43 | 31.12 |
Houlihan Lokey Inc is an investment bank with expertise in mergers and acquisitions, capital markets, financial restructuring, valuation, and strategic consulting. The firm serves corporations, institutions, and governments world-wide with offices in the United States, Europe, and the Asia-Pacific region. The company operates in three segments. In the Corporate Finance business segment, it provides M&A and capital markets advisory services. Through the Financial Restructuring business segment, the company advises on some of the complex restructurings around the world. The Financial and Valuation Advisory Services business segment provides valuation and financial opinion, and financial and strategic consulting practices in the United States.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.